Initial Results Positive For Valneva/Pfizer's Lyme Disease Vaccine In First Phase II Study
Role Of Infectious Disease Prevention Highlighted
Speciality vaccine biotech Valneva outlines seroconversion rates and safety of candidate Lyme disease vaccine that it is co-developing with partner Pfizer.
You may also be interested in...
Deal Watch: BMS Backs Out Of UniQure Gene Therapy Collaboration
The gene therapy firm announced that Bristol terminated a collaboration started in 2015. Nona follows its recent alliance with Moderna with a second collaboration, this time with Dragonfly.
Valneva’s Lyme Disease Jab Program Gets Pfizer Cash Boost
Pfizer will invest in partner Valneva’s late-stage Lyme disease jab program, providing much-needed financial support to the French firm which has suffered COVID-19 vaccine sales setbacks.
Valneva Advances New Vaccines Agenda With Top-Line Phase III Chikungunya Data
France’s Valneva has announced positive top-line Phase III data for its investigational chikungunya vaccine, and the NASDAQ- and Euronext-listed company looks set to launch the product next year.